News Archive

September 2018

• Press Release Sep 24, 2018

  Novartis announces five grant recipients of eXcellence in Ophthalmology Vision Award (XOVA) for nonprofit sustainable eye health initiatives

  A panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries  The 2018 grants support initiatives ranging from training teachers…
• Press Release Sep 22, 2018

  Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness

  In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis  was shown to be…
• Press Release Sep 22, 2018

  New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD

  Pre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period …
• Press Release Sep 21, 2018

  Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

  Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the…
• Press Release Sep 21, 2018

  Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe

  Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in…
• Press Release Sep 21, 2018

  Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease

  If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease   Children and adults…
• Press Release Sep 17, 2018

  World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime

  From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research[1]  79% are willing…
• Press Release Sep 17, 2018

  Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals

  Alcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos,…
• Press Release Sep 13, 2018

  Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients

  Real-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th…
• Press Release Sep 12, 2018

  Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS

  Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects…
• Press Release Sep 12, 2018

  Novartis survey shows psoriasis patients want treatment effect beyond clear skin

  New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no…
• Press Release Sep 11, 2018

  Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz

  Der globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg…